Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Down 36.2% in February

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 172,300 shares, a drop of 36.2% from the February 13th total of 270,200 shares. Based on an average daily trading volume, of 570,800 shares, the short-interest ratio is currently 0.3 days. Currently, 6.5% of the shares of the company are short sold.

Hedge Funds Weigh In On Traws Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $89,000. Renaissance Technologies LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $89,000. Geode Capital Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $185,000. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $252,000. Finally, Vestal Point Capital LP purchased a new position in shares of Traws Pharma in the 4th quarter worth $666,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Trading Down 0.7 %

TRAW stock opened at $2.74 on Friday. The stock has a market cap of $10.00 million, a P/E ratio of -0.02 and a beta of 1.42. Traws Pharma has a 1 year low of $2.02 and a 1 year high of $24.75. The business has a fifty day moving average price of $5.72.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.